Trial
NCT05746559
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Chronic Kidney Disease
Intervention
Placebo
Why stopped
The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22